how to withdraw in haha777
Renowned Architect Kazuyo Sejima Appointed to United States-Japan Foundation Board
China's AIMA brand electric motorbike is now in Bangladesh
Tests keep coming for Auburn and Duke, who collide at Cameron Indoor Stadium in a typical prove-it game in a rare environment on Wednesday night. No. 2 Auburn and No. 9 Duke square off less than one month into the season as two of the most battle-tested teams in basketball. They're matched as one of the marquee games in the crossover showcase known as the ACC-SEC Challenge. Auburn (7-0) jumped two spots in the latest Top 25 poll propelled by its Maui Invitational championship. In one of Feast Week's toughest brackets, the Tigers rallied from 18 points down to beat then-No. 4 Iowa State, handled then-No. 12 North Carolina 85-72 and rolled past Memphis 90-76 in the title game. With a week off to shed any remnants of jet lag returning from the islands, Auburn head coach Bruce Pearl is pointing to another potential resume-building win. "The confidence that we're going to get from (Maui) is that we know we can play with anybody," Pearl said. "I promise you this, we'll stay humble and hungry. We will not begin to think too much of ourselves." Helping lead Auburn in Maui was fifth-year power forward Johni Broome. The tournament's MVP, Broome averaged 21.7 points, 15 rebounds, 4.3 assists and three blocks in the three-game sweep. Spearheading a veteran Tigers roster, Broome couldn't care less about individual honors. "I wanted to come to a place where the foundation was already built, and that's why I came to Auburn," Broome said. "Winning player of the year doesn't matter to me. I care about winning games, and making sure I can help my team in any way." Broome's 20.7 points and 12.9 rebounds per game lead the Tigers, while Chad Baker-Mazara adds 12.6 ppg and Denver Jones chips in 11.1. Auburn's next roadblock is earning its first-ever win against Duke. The Tigers are 0-3 all-time against the Blue Devils, including a six-point loss in the 2018 Maui Invitational. Duke (5-2) has already been through three games against ranked opponents. The Blue Devils had a 77-72 loss against then-No. 19 Kentucky, a 14-point win at then-No. 17 Arizona and a 75-72 defeat against No. 1 Kansas last week in Las Vegas. "Best team we've played so far," Pearl said of Duke. Bouncing back on Friday, the Blue Devils took down Seattle 70-48, holding the Redhawks to just 10 made field goals on 47 attempts (21.3 percent). Despite the suffocating defensive effort, Duke head coach Jon Scheyer knows his team has a long way to go. "I wasn't really happy with much tonight, to be honest," Scheyer said on Friday. "I thought we rushed some shots, had too many turnovers. We need to finish stronger, drive stronger, make extra passes, there were a whole bunch of things. ... We just need to get back to practice. In fairness to our guys, we've been traveling a lot and we just need practice time." Pacing the Blue Devils in scoring is five-star freshman Cooper Flagg. He's averaging 15.9 points per game to go along with 8.3 rebounds. Fellow freshman Kon Knueppel adds 13.4 points per contest. Far less seasoned raw freshman, big man Khaman Maluach has given Duke's interior defense an edge it was lacking last season. A projected lottery pick who can be overshadowed by the Flagg publicity train, Maluach (7-2, 248) is averaging 8.4 points, 5.0 rebounds and has two three-block games. In last year's inaugural ACC-SEC Challenge, Duke lost at Arkansas 80-75 and Auburn topped Virginia Tech 74-57. --Field Level Media
TAIPEI , Dec. 6, 2024 /PRNewswire/ -- Cordyceps Sunshine Biotech Holdings Co., Ltd. 【C.S 】 Group , Taiwan's largest chain specializing in Taiwanofungus products, has officially announced its entry into the global pet medication market with a groundbreaking new drug. On November 30, 2024 , the company co-hosted the "Taiwanofungus Fungal Technology and Pharmacological Research Progress Seminar" in Taipei with the Chinese Herbal Fungi Industry Research and Development Association (CHFIRDA). During the seminar, 【C.S 】 Group revealed plans to produce a topical ointment using Antcin A , a key compound extracted from Taiwanofungus , aiming to address the demand in the global steroid-based pet medication market. Extraction and purification of the key compound in Taiwanofungus, Antcin A. Vincent Liu , director at 【C.S 】 Group , highlighted the company's unique position as one of the few biotech startups capable of vertically integrating the entire production chain—from fungal strain development, cultivation, extraction, and purification to large-scale production and distribution. It is expected that the active ingredients will be further extracted, making it an ideal candidate for the development of botanical new drugs. A report by Market Research Engine projects the global botanical drugs market to reach $47.4 billion by 2028, with a compound annual growth rate (CAGR) of 6%. Antcin A, a signature sterol compound derived from Taiwanofungus, serves as a precursor for many bioactive compounds but is challenging to extract due to its scarcity in wild strains. Leveraging proprietary breeding techniques and patent-protected cultivation methods, 【C.S 】 Group has successfully optimized the production of Antcin A, enabling scalable extraction and purification. Entering the Global Steroid-Based Pet Medication Market Dr. Jia-Xin Huang , a renowned Taiwanofungus expert, The effects of Antcin A have been recognized by the industry for a long time. However, the extraction process requires a large amount of Taiwanofungus raw materials, which is very costly and few industry players can overcome it. As a result, the market demand far exceeds the supply. If it is to be commercialized in the short term, it is very suitable to be introduced into the pet external preparation market first. Dr. Chiao Li , a U.S. listing advisor for 【C.S 】 Group , emphasized the immense potential of the global pet market, particularly in North America . According to the American Pet Products Association (APPA), as of 2017-2018, there were 84.6 million pet-owning households in the U.S., with 94.2 million cats and 89.7 million dogs. The pet industry is projected to reach $150 billion by 2024. Furthermore, Asia has emerged as a fast-growing pet market, with substantial growth momentum. In developed regions like Europe and the U.S., spending on pets—including medical care, medications, food, and insurance—is well-established. As pet ownership rises globally, fueled by aging populations and declining birth rates, demand for pet medications is expected to increase. Innovative Solutions for a Growing Market Dalan Huang , President of 【C.S 】 Group , cited a Research Nester report projecting the global pet medication market to reach $22.58 billion by 2024, with a CAGR exceeding 9.7% through 2036, potentially surpassing $69.8 billion . Steroids remain a common treatment option but are often stigmatized due to their side effects. With the anti-inflammatory efficacy of Antcin A, 【C.S 】 Group aims to introduce a novel steroid alternative that reduces reliance on conventional steroids while minimizing side effects, a solution likely to appeal to both veterinarians and pet owners. The Taiwanese pet medication market is valued at approximately NT$60 billion , with NT$12 billion attributed to livestock and NT$48 billion to pets. Taiwan's Institute for Economic Research (TIER) estimates that the pet population will reach 4 million by 2025, ensuring steady market growth. Promising Growth in the U.S. Capital Market In recent years, the U.S. capital market has introduced pet-themed ETFs, reflecting the long-term revenue potential of the pet industry, where the average pet lifespan of 10-15 years provides stable income streams resilient to economic fluctuations. 【C.S 】 Group 's classification in the U.S. stock market as a company specializing in medicinal plants is supported by its exclusive cultivation techniques for Taiwan's native Taiwanofungus . With large-scale production facilities in Taiwan , the company has achieved a CAGR of 41% in the Taiwanese market between 2023 and 2024. Building on the Asia pacific herbal health and pharmaceutical markets, 【C.S 】 Group 's expansion into the global pet steroid medication market is set to drive significant revenue growth with a bright outlook ahead. SOURCE Cordyceps Sunshine
